DMAA Enters Definitive Merger Agreement with Power Analytics Global Corp for up to $1 Billion SPAC Deal

summarizeSummary

Drugs Made In America Acquisition Corp. has entered into a definitive merger agreement with Power Analytics Global Corp, a private AI and analytics company, for a transaction valued at up to $1.0 billion, providing a critical strategic path forward for the SPAC.

check_boxKey Events

• Definitive Merger Agreement Signed

  Drugs Made In America Acquisition Corp. (DMAA) has entered into a Definitive Merger Agreement with Power Analytics Global Corp (PAGC), a Delaware corporation focused on artificial intelligence, advanced analytics, and quantum-resistant security solutions. The agreement was signed on April 29, 2026.

• Target Valuation and Floor

  The merger contemplates a target enterprise valuation for PAGC of $1.0 billion, subject to a Valuation Milestone Schedule based on verified revenue contracts. A Floor Valuation of $300 million has been established, below which parties may renegotiate or terminate the agreement.

• Post-Merger Ownership Structure

  Post-closing ownership of the surviving entity is expected to be approximately 90% held by former PAGC shareholders and 10% by existing DMAA shareholders, prior to dilution from any private investment in public equity (PIPE) issuances.

• Minimum Cash Condition

  DMAA has agreed to use commercially reasonable efforts to deliver cash at closing, targeting a minimum of $30 million, with flexibility to close at not less than $15 million, through its Trust Account and/or PIPE financing.

auto_awesomeAnalysis

This definitive merger agreement is a critical development for Drugs Made In America Acquisition Corp., especially following its recent 10-K filing which disclosed a going concern warning and material weaknesses. The agreement to combine with Power Analytics Global Corp (PAGC), an AI and analytics company, provides a clear path forward and addresses the company's previous financial uncertainties. The target valuation of up to $1.0 billion for PAGC, with a floor of $300 million, represents a substantial transaction for DMAA. While existing DMAA shareholders will experience significant dilution, this deal offers a potential lifeline and a new strategic direction in a high-growth sector. The company recently secured an extension for its business combination deadline on May 1, 2026, and this filing demonstrates the successful utilization of that extension to finalize this agreement. The transaction remains subject to shareholder approval and securing the minimum cash condition, including potential PIPE financing.